株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アンチセンスおよびRNAi治療薬の世界市場:2019年~2023年

Global Antisense and RNAi Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 318835
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
アンチセンスおよびRNAi治療薬の世界市場:2019年~2023年 Global Antisense and RNAi Therapeutics Market 2019-2023
出版日: 2018年10月25日 ページ情報: 英文 113 Pages
概要

アンチセンスおよびRNAi治療薬について

世界のアンチセンスおよびRNAi治療薬市場は、慢性肝炎、心血管疾患、ハンチントン病、さらには希少疾病などの疾患を治療できる可能性のある、新たな治療法の選択肢です。</p>

Technavioのアナリストは、世界のアンチセンスおよびRNAi治療薬市場が2019年から2023年までに8.67%のCAGRで成長すると予測しています。

当レポートでは、世界のアンチセンスおよびRNAi治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第7章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別(2018年~2023年)
  • 比較:タイプ別
  • アンチセンス療法
  • RNAi療法
  • 市場機会:タイプ別

第8章 顧客情勢

第9章 市場セグメンテーション:アプリケーション別

  • セグメンテーション:アプリケーション別
  • 心血管疾患
  • 代謝障害

第10章 地域別景観

  • 地域別セグメンテーション(2018年~2023年)
  • 地域別比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 主要国
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Alnylam Pharmaceuticals
  • Bausch Health
  • Biogen
  • Sarepta Therapeutics

第16章 付録

  • 調査方法
  • 略語のリスト

第17章 TECHNAVIOについて

図表
  • Exhibit 01: Global biologic therapeutics market
  • Exhibit 02: Segments of global biologic therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: List of pipeline molecules for antisense and RNAi therapeutics
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Antisense therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Antisense therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: RNAi therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: RNAi therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Pipeline molecules for cancer treatment
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in Americas
  • Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in EMEA
  • Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in APAC
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Alnylam Pharmaceuticals - Vendor overview
  • Exhibit 47: Alnylam Pharmaceuticals - Business segments
  • Exhibit 48: Alnylam Pharmaceuticals - Organizational developments
  • Exhibit 49: Alnylam Pharmaceuticals - Geographic focus
  • Exhibit 50: Alnylam Pharmaceuticals - Key offerings
  • Exhibit 51: Bausch Health - Vendor overview
  • Exhibit 52: Bausch Health - Business segments
  • Exhibit 53: Bausch Health - Organizational developments
  • Exhibit 54: Bausch Health - Geographic focu
  • Exhibit 55: Bausch Health - Segment focus
  • Exhibit 56: Bausch Health - Key offerings
  • Exhibit 57: Biogen - Vendor overview
  • Exhibit 58: Biogen - Business segments
  • Exhibit 59: Biogen - Organizational developments
  • Exhibit 60: Biogen - Geographic focus
  • Exhibit 61: Biogen - Key offerings
  • Exhibit 62: Sarepta Therapeutics - Vendor overview
  • Exhibit 63: Sarepta Therapeutics - Business segments
  • Exhibit 64: Sarepta Therapeutics - Organizational developments
  • Exhibit 65: Sarepta Therapeutics - Geographic focus
  • Exhibit 66: Sarepta Therapeutics - Key offerings
  • Exhibit 67: Validation techniques employed for market sizing
  • Exhibit 68: List of abbreviations
目次
Product Code: IRTNTR30107

About Antisense and RNAi Therapeutics

Antisense and RNAi therapeutics are novel therapeutic options with potential to treat diseases such as chronic liver and cardiovascular diseases, Huntington disease, and even rare diseases.

Technavio's analysts forecast the Global Antisense and RNAi Therapeutics Market to grow at a CAGR of 8.67% during the period 2019-2023.

Covered in this report

The report covers the present scenario and the growth prospects of the antisense and RNAi therapeutics market. To calculate the market size, the report considers the revenue generated from the application of antisense and RNAi therapeutics across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Antisense and RNAi Therapeutics Market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Alnylam Pharmaceuticals
  • Bausch Health
  • Biogen
  • Sarepta Therapeutics

Market driver

  • High target affinity and specificity of RNAi therapeutics

Market challenge

  • High price of RNAi drugs

Market trend

  • Growing potential to address multiple therapy areas

Key questions answered in this report:

  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Antisense therapy - Market size and forecast 2018-2023
  • RNAi therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Cardiovascular diseases
  • Cancer
  • Metabolic disorders

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Alnylam Pharmaceuticals
  • Bausch Health
  • Biogen
  • Sarepta Therapeutics

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations

PART 17: EXPLORE TECHNAVIO

Back to Top